EDITOR,-The datasheet for Inderal (propranolol) states specifically that the drug is contraindicated in patients with asthma or a history of bronchospasm. Despite this, and despite the well known risks of non-selective I blockers in patients with asthma, over the past few years Zeneca has received a number of reports of cases in which an asthmatic patient died as a result of being prescribed propranolol.
who might be prescribed propranolol erroneously, Zeneca has decided to highlight the warnings concerning asthma in the patient information leaflet for Inderal and related products. Pack labels will also carry warnings. Doctors should prescribe original packs so that a last line of defence against incorrect prescribing is not breached.
Current advice in the prescribing information for Inderal recommends that bronchospasm can usually be reversed with a 02 agonist bronchodilator such as salbutamol, although large doses may be required and the dose should be titrated according to the clinical response. As 02 adrenoceptors are blocked by propranolol the advice will now be augmented by the statement that ipratropium and intravenous aminophylline may also be indicated. We have now eliminated the bias by modifying the fitting process.3 We have also added data on a nationally representative sample of 1.5-4.5 year old children to the reference dataset.4 Compared with the original reference, the revised median weight for girls is reduced by a standard deviation score of up to 0.2 (180 g) at 9 months, while that for boys is unchanged. The line indicating a standard deviation score of -2.0 for girls ( (1974) .4 Although the selection of subjects precludes any direct comparison with the mean weights of the standards, it is interesting that there is a considerable discrepancy between the 1990 standard deviation scores of the otherwise homologous boys and girls in the study group at 3 months, which, as Wright and colleagues note, places more girls than boys below the mean. 
